Home › Cancer (all types) › NCT06997185

Communicating Uncertainties Associated With the Benefits and Risks of New Cancer Drugs

Who can join

Ages 18 and older · All sexes · Healthy volunteers welcome

Inclusion Criteria:

* Adults 18 years of age and older
* Adults fluent in English
* Adults residing in the United States

Exclusion Criteria:

* Participants who do not meet each of the 3 inclusion criteria

About the study

This nationally representative randomized survey of US adults will evaluate the effect of using brief statements to communicate different sources of uncertainty about the benefits and harms of new cancer drugs on participants' decisions and understanding.

What is being tested

• Statement communicating uncertainty with a single arm trial (other)
• Statement communicating uncertainty with limited study duration (other)
• Statement communicating uncertainty with a limited study population (other)
• Statement communicating uncertainty with an unvalidated surrogate endpoint (other)
• Statement communicating uncertainty with treatment effect size (other)

Sponsor: London School of Economics and Political Science · Participants: 3,000 · Started: May 9, 2025

Contact the study team

• Avi Cherla · Phone: 16172011718

Official record on ClinicalTrials.gov — NCT06997185

Locations in the U.S.

Conditions

• Cancer (all types)

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.